Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Diabetes Care ; 23(4): 504-9, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10857943

ABSTRACT

OBJECTIVE: The pilot study examined the ability of octreotide to retard progression of diabetic retinopathy (DR) and delay the need for panretinal photocoagulation (PRP) in patients with advanced stages of retinal disease. RESEARCH DESIGN AND METHODS: Patients with severe nonproliferative DR (NPDR) or early non-high-risk proliferative DR (PDR) were randomly assigned to conventional diabetes management (control group, 12 patients) or to treatment with maximally tolerated doses of octreotide (200-5,000 microg/day subcutaneously; 11 patients). Ocular changes in each eye were assessed at a minimum of every 3 months for 15 months or until disease progressed to high-risk PDR requiring laser surgery. Endocrine assessments occurred at 3-month intervals during the study RESULTS: Only 1 of 22 eyes from patients treated with octreotide reached high-risk PDR requiring PRP, compared with control patients, in whom 9 of 24 eyes required PRP. The decreased incidence of progression requiring laser surgery was statistically significant if events were considered independently (P < 0.006). The incidence of ocular disease progression was only 27% in patients treated with octreotide compared with 42% in patients with conventional diabetes management. This treatment effect on whether the retina worsened approached statistical significance using repeated measures analysis (P = 0.0605). Endocrine management was similar between treatment groups. Thyroxine replacement therapy was administered to maintain a euthyroid state for all octreotide-treated patients and 7 of 12 control patients. CONCLUSIONS: Our results suggest that octreotide treatment in euthyroid patients may retard progression of advanced DR and may delay the time to laser surgery.


Subject(s)
Diabetic Retinopathy/drug therapy , Octreotide/therapeutic use , Diabetes Mellitus, Type 1/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Diabetic Retinopathy/physiopathology , Disease Progression , Female , Glycated Hemoglobin/analysis , Humans , Infusions, Intravenous , Injections, Subcutaneous , Insulin-Like Growth Factor I/metabolism , Male , Octreotide/administration & dosage , Pilot Projects , Vasoconstrictor Agents/administration & dosage , Vasoconstrictor Agents/therapeutic use
2.
Can J Ophthalmol ; 24(5): 216-20, 1989 Aug.
Article in English | MEDLINE | ID: mdl-2766087

ABSTRACT

A survey of 595 metropolitan Toronto residents aged 16 years or older was done during 1986-87 to assess their interest in organ and tissue donation in general and their willingness to donate eyes in particular. Subjects were selected at random from the telephone directory and were interviewed on the telephone with a prepared questionnaire. Most of the respondents were aware of the value and types of organ and tissue transplantation. Although 63% expressed a willingness to donate body parts, only 37% had signed the organ donation portion of their driver's licence or an organ donor card. The respondents who were unwilling to donate body parts expressed certain deep-rooted anxieties and fears. More public education is needed to allay the fears and misunderstandings that remain in the minds of many potential donors.


Subject(s)
Attitude , Eye Banks , Tissue Banks , Tissue Donors , Tissue and Organ Procurement , Data Collection , Human Body , Humans , Surveys and Questionnaires , Telephone
SELECTION OF CITATIONS
SEARCH DETAIL
...